GleamWall
中文EN

TYRA Tyra Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1863127 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-52.1%
TTM EPS YoY-39.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-34.9%
ROA-33.0%
ROIC (approx.)-63.3%
Asset turnover—

Leverage & solvency

Liabilities / assets4.8%
Debt / equity0.00x
Current ratio23.93x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.70x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$43.14M$39.20M$33.47M$28.19M$25.47M$24.31M$24.96M$22.18M
SG&A expense$11.74M$9.81M$8.53M$8.33M$7.47M$7.14M$6.89M$7.56M
Operating income-$54.88M-$49.00M-$42.00M-$36.52M-$32.94M-$31.45M-$31.85M-$29.74M
Net income-$51.12M-$45.56M-$39.30M-$33.83M-$29.87M-$28.10M-$28.15M-$25.57M
EBITDA-$54.76M-$48.87M-$41.86M-$36.38M-$32.81M-$31.31M-$31.71M-$29.60M
EPS (basic)-0.74-0.69-0.64—-0.50-0.47-0.47—
EPS (diluted)-0.74-0.69-0.64—-0.50-0.47-0.47—
Weighted avg. shares (diluted)69.08M65.99M61.75M—59.67M59.55M59.34M—
Balance sheet
Cash & equivalents$456.02M$73.83M$84.95M$77.39M$61.95M$98.49M$100.72M$92.97M
Current assets$711.62M$366.97M$394.61M$265.45M$281.22M$302.15M$324.57M$347.46M
PP&E, net$1.08M$1.17M$1.22M$1.31M$1.35M$1.41M$1.52M$1.65M
Total assets$727.53M$383.36M$412.04M$282.61M$301.85M$321.50M$343.48M$363.56M
Current liabilities$29.74M$24.62M$19.26M$18.09M$15.88M$13.77M$14.25M$14.59M
Total liabilities$34.68M$29.70M$24.46M$23.43M$21.34M$19.35M$19.94M$20.41M
Shareholders' equity$692.84M$353.66M$387.57M$259.18M$280.51M$302.15M$323.53M$343.15M
Shares outstanding68.98M59.66M59.47M53.71M53.32M53.23M53.09M50.75M
Cash flow statement
Operating cash flow-$32.21M-$31.08M-$32.57M-$23.62M-$22.38M-$23.68M-$25.46M-$19.59M
Capital expenditure$90,000$66,000$88,000$57,000$39,000$31,000$14,000$6,000
Free cash flow-$32.30M-$31.14M-$32.66M-$23.68M-$22.42M-$23.71M-$25.47M-$19.60M
Investing cash flow$34.92M$17.85M-$120.24M$34.38M-$14.81M$20.87M$32.03M$6.96M
Financing cash flow$379.47M$2.10M$160.38M$4.68M$647,000$583,000$2.19M$706,000
Depreciation & amortization$130,000$138,000$138,000$132,000$131,000$140,000$143,000$144,000
Stock-based compensation$12.16M$10.23M$7.85M$7.63M$7.58M$6.38M$6.42M$6.70M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.